- Home
- CHRS
as 07-26-2024 4:00pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 145.7M | IPO Year: | 2014 |
| Target Price: | $8.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $5.46 | Next Earning Date: | 08-05-2024 |
| Revenue: | $301,871,000 | Revenue Growth: | 64.63% |
| Revenue Growth (this year): | 3.72% | Revenue Growth (next year): | 28.27% |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
Coherus BioSciences Grants Apotex License to Distribute Toripalimab in Canada
MT Newswires
a month ago
Baird Trims Price Target on Coherus BioSciences to $8 From $9, Maintains Outperform Rating
BioPharma Dive
a month ago
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
MT Newswires
a month ago
Coherus BioSciences to Sell Yusimry to Hong Kong King-Friend Industrial in $40 Million Cash Transaction
GlobeNewswire
a month ago
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.